Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis

TNF-related apoptosis-inducing ligand (TRAIL), a promising novel anti-cancer cytokine of the TNF superfamily, and Bortezomib, the first-in-class clinically used proteasome inhibitor, alone or in combination have been shown to efficiently kill numerous tumor cell lines. However, data concerning prima...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Koschny, Ronald (VerfasserIn) , Holland, Heidrun (VerfasserIn) , Sykora, Jaromir (VerfasserIn) , Erdal, Hande (VerfasserIn) , Krupp, Wolfgang (VerfasserIn) , Bauer, Manfred (VerfasserIn) , Bockmuehl, Ulrike (VerfasserIn) , Ahnert, Peter (VerfasserIn) , Meixensberger, Jürgen (VerfasserIn) , Stremmel, Wolfgang (VerfasserIn) , Walczak, Henning (VerfasserIn) , Ganten, Tom M. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2010
In: Journal of neuro-oncology
Year: 2010, Jahrgang: 97, Heft: 2, Pages: 171-185
ISSN:1573-7373
DOI:10.1007/s11060-009-0010-6
Online-Zugang:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11060-009-0010-6
Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s11060-009-0010-6
Volltext
Verfasserangaben:Ronald Koschny, Heidrun Holland, Jaromir Sykora, Hande Erdal, Wolfgang Krupp, Manfred Bauer, Ulrike Bockmuehl, Peter Ahnert, Jürgen Meixensberger, Wolfgang Stremmel, Henning Walczak, Tom M. Ganten

MARC

LEADER 00000caa a2200000 c 4500
001 1839789298
003 DE-627
005 20230710145503.0
007 cr uuu---uuuuu
008 230322s2010 xx |||||o 00| ||eng c
024 7 |a 10.1007/s11060-009-0010-6  |2 doi 
035 |a (DE-627)1839789298 
035 |a (DE-599)KXP1839789298 
035 |a (OCoLC)1389806934 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Koschny, Ronald  |d 1974-  |e VerfasserIn  |0 (DE-588)124377483  |0 (DE-627)70661836X  |0 (DE-576)185833950  |4 aut 
245 1 0 |a Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis  |c Ronald Koschny, Heidrun Holland, Jaromir Sykora, Hande Erdal, Wolfgang Krupp, Manfred Bauer, Ulrike Bockmuehl, Peter Ahnert, Jürgen Meixensberger, Wolfgang Stremmel, Henning Walczak, Tom M. Ganten 
264 1 |c 2010 
300 |a 15 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online veröffentlicht am 20. September 2009 
500 |a Gesehen am 22.03.2023 
520 |a TNF-related apoptosis-inducing ligand (TRAIL), a promising novel anti-cancer cytokine of the TNF superfamily, and Bortezomib, the first-in-class clinically used proteasome inhibitor, alone or in combination have been shown to efficiently kill numerous tumor cell lines. However, data concerning primary human tumor cells are very rare. Using primary esthesioneuroblastoma cells we analyzed the anti-tumor potential and the mechanism employed by Bortezomib in combination with TRAIL for the treatment of this rare but aggressive tumor. Expression of components of the TRAIL pathway was analyzed in tumor specimens and isolated primary tumor cells at the protein level. Cells were treated with TRAIL, Bortezomib, and a combination thereof, and apoptosis induction was quantified. Clonogenicity assays were performed to elucidate the long-term effect of this treatment. Despite expressing all components of the TRAIL pathway, freshly isolated primary esthesioneuroblastoma cells were completely resistant to TRAIL-induced apoptosis. They could, however, be very efficiently sensitized by subtoxic doses of Bortezomib. The influence of Bortezomib on the TRAIL pathway was analyzed and showed upregulation of TRAIL death receptor expression, enhancement of the TRAIL death-inducing signaling complex (DISC), and downregulation of anti-apoptotic proteins of the TRAIL pathway. Of clinical relevance, TRAIL-resistant primary tumor cells could be repeatedly sensitized by Bortezomib, providing the basis for repeated clinical application schedules. This is the first report on the highly synergistic induction of apoptosis in primary esthesioneuroblastoma cells by Bortezomib and TRAIL. This combination, therefore, represents a promising novel therapeutic option for esthesioneuroblastoma. 
650 4 |a Apoptosis 
650 4 |a Bortezomib 
650 4 |a Esthesioneuroblastoma 
650 4 |a Primary tumor cells 
650 4 |a TRAIL 
700 1 |a Holland, Heidrun  |e VerfasserIn  |4 aut 
700 1 |a Sykora, Jaromir  |d 1982-  |e VerfasserIn  |0 (DE-588)1055033599  |0 (DE-627)792537815  |0 (DE-576)411120182  |4 aut 
700 1 |a Erdal, Hande  |d 1985-  |e VerfasserIn  |0 (DE-588)1043822828  |0 (DE-627)770957390  |0 (DE-576)395932238  |4 aut 
700 1 |a Krupp, Wolfgang  |e VerfasserIn  |4 aut 
700 1 |a Bauer, Manfred  |e VerfasserIn  |4 aut 
700 1 |a Bockmuehl, Ulrike  |e VerfasserIn  |4 aut 
700 1 |a Ahnert, Peter  |e VerfasserIn  |4 aut 
700 1 |a Meixensberger, Jürgen  |e VerfasserIn  |4 aut 
700 1 |a Stremmel, Wolfgang  |d 1952-  |e VerfasserIn  |0 (DE-588)142773638  |0 (DE-627)640118747  |0 (DE-576)33331560X  |4 aut 
700 1 |a Walczak, Henning  |d 1966-  |e VerfasserIn  |0 (DE-588)172932513  |0 (DE-627)697859703  |0 (DE-576)133786773  |4 aut 
700 1 |a Ganten, Tom M.  |d 1969-  |e VerfasserIn  |0 (DE-588)115539670  |0 (DE-627)69139010X  |0 (DE-576)289938899  |4 aut 
773 0 8 |i Enthalten in  |t Journal of neuro-oncology  |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1983  |g 97(2010), 2, Seite 171-185  |h Online-Ressource  |w (DE-627)32046122X  |w (DE-600)2007293-4  |w (DE-576)107058944  |x 1573-7373  |7 nnas  |a Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis 
773 1 8 |g volume:97  |g year:2010  |g number:2  |g pages:171-185  |g extent:15  |a Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis 
856 4 0 |u https://doi.org/10.1007/s11060-009-0010-6  |x Resolving-System  |x Verlag  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://link.springer.com/article/10.1007/s11060-009-0010-6  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20230322 
993 |a Article 
994 |a 2010 
998 |g 115539670  |a Ganten, Tom M.  |m 115539670:Ganten, Tom M.  |d 50000  |e 50000PG115539670  |k 0/50000/  |p 12  |y j 
998 |g 172932513  |a Walczak, Henning  |m 172932513:Walczak, Henning  |d 50000  |e 50000PW172932513  |k 0/50000/  |p 11 
998 |g 142773638  |a Stremmel, Wolfgang  |m 142773638:Stremmel, Wolfgang  |d 910000  |d 910100  |e 910000PS142773638  |e 910100PS142773638  |k 0/910000/  |k 1/910000/910100/  |p 10 
998 |g 1043822828  |a Erdal, Hande  |m 1043822828:Erdal, Hande  |d 50000  |e 50000PE1043822828  |k 0/50000/  |p 4 
998 |g 1055033599  |a Sykora, Jaromir  |m 1055033599:Sykora, Jaromir  |d 50000  |e 50000PS1055033599  |k 0/50000/  |p 3 
998 |g 124377483  |a Koschny, Ronald  |m 124377483:Koschny, Ronald  |d 910000  |d 910100  |e 910000PK124377483  |e 910100PK124377483  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1839789298  |e 4294933097 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"15 S."}],"person":[{"given":"Ronald","family":"Koschny","display":"Koschny, Ronald","role":"aut"},{"given":"Heidrun","family":"Holland","display":"Holland, Heidrun","role":"aut"},{"display":"Sykora, Jaromir","family":"Sykora","given":"Jaromir","role":"aut"},{"display":"Erdal, Hande","family":"Erdal","given":"Hande","role":"aut"},{"display":"Krupp, Wolfgang","family":"Krupp","given":"Wolfgang","role":"aut"},{"role":"aut","family":"Bauer","display":"Bauer, Manfred","given":"Manfred"},{"role":"aut","display":"Bockmuehl, Ulrike","family":"Bockmuehl","given":"Ulrike"},{"display":"Ahnert, Peter","family":"Ahnert","given":"Peter","role":"aut"},{"given":"Jürgen","family":"Meixensberger","display":"Meixensberger, Jürgen","role":"aut"},{"given":"Wolfgang","family":"Stremmel","display":"Stremmel, Wolfgang","role":"aut"},{"role":"aut","given":"Henning","display":"Walczak, Henning","family":"Walczak"},{"role":"aut","display":"Ganten, Tom M.","family":"Ganten","given":"Tom M."}],"title":[{"title":"Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis","title_sort":"Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis"}],"relHost":[{"disp":"Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosisJournal of neuro-oncology","pubHistory":["1.1983 -"],"note":["Gesehen am 11.06.2018","Fortsetzung der Druck-Ausgabe"],"recId":"32046122X","language":["eng"],"id":{"eki":["32046122X"],"zdb":["2007293-4"],"issn":["1573-7373"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"1983-","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","dateIssuedKey":"1983","publisher":"Springer Science + Business Media B.V ; Kluwer"}],"part":{"text":"97(2010), 2, Seite 171-185","pages":"171-185","volume":"97","issue":"2","extent":"15","year":"2010"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Journal of neuro-oncology","title":"Journal of neuro-oncology"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1839789298"],"doi":["10.1007/s11060-009-0010-6"]},"language":["eng"],"origin":[{"dateIssuedDisp":"2010","dateIssuedKey":"2010"}],"name":{"displayForm":["Ronald Koschny, Heidrun Holland, Jaromir Sykora, Hande Erdal, Wolfgang Krupp, Manfred Bauer, Ulrike Bockmuehl, Peter Ahnert, Jürgen Meixensberger, Wolfgang Stremmel, Henning Walczak, Tom M. Ganten"]},"note":["Online veröffentlicht am 20. September 2009","Gesehen am 22.03.2023"],"recId":"1839789298"} 
SRT |a KOSCHNYRONBORTEZOMIB2010